초대 간세포 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for primary hepatocytes. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global primary hepatocytes market from 2025 to 2032.

Key Insights:

• Primary Hepatocytes Market Size (2025E): US$ 272.9 Mn
• Projected Market Value (2032F): US$ 428.2 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 6.6%

Primary Hepatocytes Market - Report Scope:

Primary hepatocytes are specialized liver cells that serve as essential tools for pharmaceutical research, toxicity testing, and drug development. These cells are widely used in drug discovery, hepatotoxicity testing, and in-vitro models for liver diseases. The primary hepatocytes market caters to research institutions, pharmaceutical companies, and contract research organizations (CROs), offering a variety of hepatocyte products, including human primary hepatocytes, rat hepatocytes, and immortalized hepatocytes. Market growth is driven by increasing demand for personalized medicine, advancements in cell culture technology, and the rising need for more accurate drug testing models.

Market Growth Drivers:

The global primary hepatocytes market is propelled by several key factors, including the growing demand for personalized medicine and the rising need for reliable in-vitro testing models in drug discovery and toxicity testing. Hepatocytes are crucial in assessing liver function, metabolizing compounds, and studying liver diseases, leading to their widespread adoption in pharmaceutical R&D. Technological advancements, such as the development of advanced hepatocyte isolation techniques and improved cell culture systems, have enhanced the performance and utility of primary hepatocytes, further boosting market expansion. Moreover, the growing focus on non-animal testing methods and the increasing number of liver-related diseases contribute to the rising adoption of primary hepatocytes in medical research.

Market Restraints:

Despite promising growth prospects, the primary hepatocytes market faces challenges related to the high cost of primary hepatocyte isolation and culture systems. These techniques require specialized equipment and skilled personnel, which can limit the accessibility of primary hepatocytes to smaller laboratories or institutions with limited budgets. Additionally, the limited supply of human liver tissue and ethical concerns associated with sourcing hepatocytes can pose significant barriers to market growth. Regulatory hurdles and the need for compliance with stringent guidelines in pharmaceutical research further complicate market entry for new players.

Market Opportunities:

The primary hepatocytes market presents significant growth opportunities driven by innovations in cell culture technology, advancements in liver disease research, and increasing demand for alternative drug testing models. The rise in chronic liver diseases such as cirrhosis and hepatitis, along with the growing adoption of personalized medicine approaches, provides new avenues for market players to develop more effective hepatocyte-based solutions. Strategic partnerships between pharmaceutical companies, CROs, and research institutions, alongside investments in R&D, are crucial to capitalize on emerging opportunities and sustain market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the primary hepatocytes market globally?
• Which hepatocyte types and applications are driving the demand for primary hepatocytes across different research settings?
• How are technological advancements reshaping the competitive landscape of the primary hepatocytes market?
• Who are the key players contributing to the primary hepatocytes market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global primary hepatocytes market?

Competitive Intelligence and Business Strategy:

Leading players in the global primary hepatocytes market, including Thermo Fisher Scientific, Lonza Group, and Merck KGaA, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced hepatocyte culture systems, liver-on-a-chip models, and improved hepatocyte isolation techniques, catering to diverse research needs. Collaborations with pharmaceutical companies, biotechnology firms, and academic research institutions facilitate market access and promote the development of more effective hepatocyte-based solutions. Moreover, emphasis on clinical research, drug development, and regulatory compliance fosters market growth and enhances product offerings in the evolving hepatocyte market.

Key Companies Profiled:

• Thermo Fisher Scientific
• Lonza Group
• Merck KGaA
• Sigma-Aldrich (now part of Merck)
• BioIVT
• CellzDirect (a part of Thermo Fisher)
• In Vitro Technologies
• Primorigen Biosciences
• PharmaCyte Biotech
• Wuxi AppTec

Global Primary Hepatocytes Market Segmentation

By Product

• Cryopreserved Suspension Hepatocytes
• Fresh Suspension Hepatocytes
• 3D (Spheroid) Hepatocytes
• Expanded Hepatocytes (Plateable)
• Non-characterized Hepatocytes

By Species

• Human
• Rat
• Mouse
• Dog
• Monkey
• Horse

By Application/Assay

• Cell Viability Assay
• Cytochrome Enzyme Activity
• High Content Cytotoxicity
• Transporter Inhibition Assay
• In Vitro Intrinsic Clearance
• Phospholipids Assay

By End User

• Biopharmaceutical companies
• Academic and Research institutes
• Contract Research Organizations

By Region

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Primary Hepatocytes Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Global Primary Hepatocytes Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Primary Hepatocytes Market Outlook: Product
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 4.3.3.1. Cryopreserved Suspension Hepatocytes
    • 4.3.3.2. Fresh Suspension Hepatocytes
    • 4.3.3.3. 3D (Spheroid) Hepatocytes
    • 4.3.3.4. Expanded Hepatocytes (Plateable)
    • 4.3.3.5. Non-characterized Hepatocytes
  • 4.3.4. Market Attractiveness Analysis: Product
• 4.4. Global Primary Hepatocytes Market Outlook: Species
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Species, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
    • 4.4.3.1. Human
    • 4.4.3.2. Rat
    • 4.4.3.3. Mouse
    • 4.4.3.4. Dog
    • 4.4.3.5. Monkey
    • 4.4.3.6. Horse
    • 4.4.3.7. Others
  • 4.4.4. Market Attractiveness Analysis: Species
• 4.5. Global Primary Hepatocytes Market Outlook: Application/Assay
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Application/Assay, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
    • 4.5.3.1. Cell Viability Assay
    • 4.5.3.2. Cytochrome Enzyme Activity
    • 4.5.3.3. High Content Cytotoxicity
    • 4.5.3.4. Transporter Inhibition Assay
    • 4.5.3.5. In Vitro Intrinsic Clearance
    • 4.5.3.6. Phospholipids Assay
    • 4.5.3.7. Others
  • 4.5.4. Market Attractiveness Analysis: Application/Assay
• 4.6. Global Primary Hepatocytes Market Outlook: End User
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
  • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 4.6.3.1. Biopharmaceutical companies
    • 4.6.3.2. Academic and Research institutes
    • 4.6.3.3. Contract Research Organizations
  • 4.6.4. Market Attractiveness Analysis: End User

5. Global Primary Hepatocytes Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Primary Hepatocytes Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Product
  • 6.2.3. By Species
  • 6.2.4. By Application/Assay
  • 6.2.5. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 6.4.1. Cryopreserved Suspension Hepatocytes
  • 6.4.2. Fresh Suspension Hepatocytes
  • 6.4.3. 3D (Spheroid) Hepatocytes
  • 6.4.4. Expanded Hepatocytes (Plateable)
  • 6.4.5. Non-characterized Hepatocytes
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 6.5.1. Human
  • 6.5.2. Rat
  • 6.5.3. Mouse
  • 6.5.4. Dog
  • 6.5.5. Monkey
  • 6.5.6. Horse
  • 6.5.7. Others
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 6.6.1. Cell Viability Assay
  • 6.6.2. Cytochrome Enzyme Activity
  • 6.6.3. High Content Cytotoxicity
  • 6.6.4. Transporter Inhibition Assay
  • 6.6.5. In Vitro Intrinsic Clearance
  • 6.6.6. Phospholipids Assay
  • 6.6.7. Others
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 6.7.1. Biopharmaceutical companies
  • 6.7.2. Academic and Research institutes
  • 6.7.3. Contract Research Organizations
• 6.8. Market Attractiveness Analysis

7. Europe Primary Hepatocytes Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Product
  • 7.2.3. By Species
  • 7.2.4. By Application/Assay
  • 7.2.5. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 7.4.1. Cryopreserved Suspension Hepatocytes
  • 7.4.2. Fresh Suspension Hepatocytes
  • 7.4.3. 3D (Spheroid) Hepatocytes
  • 7.4.4. Expanded Hepatocytes (Plateable)
  • 7.4.5. Non-characterized Hepatocytes
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 7.5.1. Human
  • 7.5.2. Rat
  • 7.5.3. Mouse
  • 7.5.4. Dog
  • 7.5.5. Monkey
  • 7.5.6. Horse
  • 7.5.7. Others
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 7.6.1. Cell Viability Assay
  • 7.6.2. Cytochrome Enzyme Activity
  • 7.6.3. High Content Cytotoxicity
  • 7.6.4. Transporter Inhibition Assay
  • 7.6.5. In Vitro Intrinsic Clearance
  • 7.6.6. Phospholipids Assay
  • 7.6.7. Others
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 7.7.1. Biopharmaceutical companies
  • 7.7.2. Academic and Research institutes
  • 7.7.3. Contract Research Organizations
• 7.8. Market Attractiveness Analysis

8. East Asia Primary Hepatocytes Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Product
  • 8.2.3. By Species
  • 8.2.4. By Application/Assay
  • 8.2.5. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 8.4.1. Cryopreserved Suspension Hepatocytes
  • 8.4.2. Fresh Suspension Hepatocytes
  • 8.4.3. 3D (Spheroid) Hepatocytes
  • 8.4.4. Expanded Hepatocytes (Plateable)
  • 8.4.5. Non-characterized Hepatocytes
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 8.5.1. Human
  • 8.5.2. Rat
  • 8.5.3. Mouse
  • 8.5.4. Dog
  • 8.5.5. Monkey
  • 8.5.6. Horse
  • 8.5.7. Others
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 8.6.1. Cell Viability Assay
  • 8.6.2. Cytochrome Enzyme Activity
  • 8.6.3. High Content Cytotoxicity
  • 8.6.4. Transporter Inhibition Assay
  • 8.6.5. In Vitro Intrinsic Clearance
  • 8.6.6. Phospholipids Assay
  • 8.6.7. Others
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 8.7.1. Biopharmaceutical companies
  • 8.7.2. Academic and Research institutes
  • 8.7.3. Contract Research Organizations
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Primary Hepatocytes Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Product
  • 9.2.3. By Species
  • 9.2.4. By Application/Assay
  • 9.2.5. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 9.4.1. Cryopreserved Suspension Hepatocytes
  • 9.4.2. Fresh Suspension Hepatocytes
  • 9.4.3. 3D (Spheroid) Hepatocytes
  • 9.4.4. Expanded Hepatocytes (Plateable)
  • 9.4.5. Non-characterized Hepatocytes
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 9.5.1. Human
  • 9.5.2. Rat
  • 9.5.3. Mouse
  • 9.5.4. Dog
  • 9.5.5. Monkey
  • 9.5.6. Horse
  • 9.5.7. Others
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 9.6.1. Cell Viability Assay
  • 9.6.2. Cytochrome Enzyme Activity
  • 9.6.3. High Content Cytotoxicity
  • 9.6.4. Transporter Inhibition Assay
  • 9.6.5. In Vitro Intrinsic Clearance
  • 9.6.6. Phospholipids Assay
  • 9.6.7. Others
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 9.7.1. Biopharmaceutical companies
  • 9.7.2. Academic and Research institutes
  • 9.7.3. Contract Research Organizations
• 9.8. Market Attractiveness Analysis

10. Latin America Primary Hepatocytes Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Product
  • 10.2.3. By Species
  • 10.2.4. By Application/Assay
  • 10.2.5. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 10.4.1. Cryopreserved Suspension Hepatocytes
  • 10.4.2. Fresh Suspension Hepatocytes
  • 10.4.3. 3D (Spheroid) Hepatocytes
  • 10.4.4. Expanded Hepatocytes (Plateable)
  • 10.4.5. Non-characterized Hepatocytes
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 10.5.1. Human
  • 10.5.2. Rat
  • 10.5.3. Mouse
  • 10.5.4. Dog
  • 10.5.5. Monkey
  • 10.5.6. Horse
  • 10.5.7. Others
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 10.6.1. Cell Viability Assay
  • 10.6.2. Cytochrome Enzyme Activity
  • 10.6.3. High Content Cytotoxicity
  • 10.6.4. Transporter Inhibition Assay
  • 10.6.5. In Vitro Intrinsic Clearance
  • 10.6.6. Phospholipids Assay
  • 10.6.7. Others
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 10.7.1. Biopharmaceutical companies
  • 10.7.2. Academic and Research institutes
  • 10.7.3. Contract Research Organizations
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Primary Hepatocytes Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Product
  • 11.2.3. By Species
  • 11.2.4. By Application/Assay
  • 11.2.5. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 11.4.1. Cryopreserved Suspension Hepatocytes
  • 11.4.2. Fresh Suspension Hepatocytes
  • 11.4.3. 3D (Spheroid) Hepatocytes
  • 11.4.4. Expanded Hepatocytes (Plateable)
  • 11.4.5. Non-characterized Hepatocytes
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Species, 2025-2032
  • 11.5.1. Human
  • 11.5.2. Rat
  • 11.5.3. Mouse
  • 11.5.4. Dog
  • 11.5.5. Monkey
  • 11.5.6. Horse
  • 11.5.7. Others
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application/Assay, 2025-2032
  • 11.6.1. Cell Viability Assay
  • 11.6.2. Cytochrome Enzyme Activity
  • 11.6.3. High Content Cytotoxicity
  • 11.6.4. Transporter Inhibition Assay
  • 11.6.5. In Vitro Intrinsic Clearance
  • 11.6.6. Phospholipids Assay
  • 11.6.7. Others
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 11.7.1. Biopharmaceutical companies
  • 11.7.2. Academic and Research institutes
  • 11.7.3. Contract Research Organizations
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Thermo Fisher Scientific Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Merck KGaA
  • 12.3.3. Lonza
  • 12.3.4. Takara Bio Inc.
  • 12.3.5. American Type Culture Collection (ATCC)
  • 12.3.6. Corning Inc.
  • 12.3.7. Cell Biologics, Inc.
  • 12.3.8. Creative Bioarray
  • 12.3.9. Axol Bioscience Ltd.
  • 12.3.10. HiMedia Laboratories
  • 12.3.11. NEXEL Co., Ltd.
  • 12.3.12. AnaBios
  • 12.3.13. Cytes Biotechnologies S.L.
  • 12.3.14. ZenBio, Inc. (BioIVT)
  • 12.3.15. iXCells Biotechnologies
  • 12.3.16. ScienCell Research Laboratories, Inc.
  • 12.3.17. Kerafast
  • 12.3.18. Kosheeka
  • 12.3.19. XenoTech
  • 12.3.20. LifeNet Health LifeSciences
  • 12.3.21. Cell Guidance Systems LLC
  • 12.3.22. Applied Biological Materials Inc. (abm)
  • 12.3.23. Discovery Life Sciences
  • 12.3.24. Innoprot
  • 12.3.25. Novabiosis

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations